Kenneth S. Cohen

8.6k total citations · 1 hit paper
68 papers, 3.3k citations indexed

About

Kenneth S. Cohen is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Kenneth S. Cohen has authored 68 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 14 papers in Oncology and 13 papers in Genetics. Recurrent topics in Kenneth S. Cohen's work include Angiogenesis and VEGF in Cancer (15 papers), Lymphoma Diagnosis and Treatment (11 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Kenneth S. Cohen is often cited by papers focused on Angiogenesis and VEGF in Cancer (15 papers), Lymphoma Diagnosis and Treatment (11 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Kenneth S. Cohen collaborates with scholars based in United States, Tanzania and Australia. Kenneth S. Cohen's co-authors include David T. Scadden, Dan G. Duda, Rakesh K. Jain, Dai Fukumura, Rachael Klein, Patrick Au, Emmanuelle di Tomaso, Wilmer B. Eames, Sandra Jean O’Neal and Roderick P. Martin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Kenneth S. Cohen

64 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo

2005 322 citations Mark Stroh, John P. Zimmer et al. Nature Medicine profile →

Peers

Countries citing papers authored by Kenneth S. Cohen

Since Specialization

Citations

This map shows the geographic impact of Kenneth S. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth S. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth S. Cohen more than expected).

Fields of papers citing papers by Kenneth S. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth S. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth S. Cohen. The network helps show where Kenneth S. Cohen may publish in the future.

Co-authorship network of co-authors of Kenneth S. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth S. Cohen. A scholar is included among the top collaborators of Kenneth S. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth S. Cohen. Kenneth S. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL 2025 ·Blood Advances ·Kirk E. Cahill, James Godfrey, Chadi Nabhan, Justin Kline, Peter A. Riedell, Kenneth S. Cohen, Sunil Narula, Theodore Karrison, (unknown), Reem Karmali, Parameswaran Venugopal, (unknown), Aaron P. Rapoport, Seung‐Tae Lee, Jennie Y. Law, Paul A. S. Fishkin, Iris Isufi, Mario R. Velasco, Lynne Kaminer, Sonali M. Smith	0
2	Efficacy and Safety of Mechanical IVC Filtration for Preventing Pulmonary Embolism in High-Risk Orthopedic Patients Undergoing Total Hip or Knee Arthroplasty 2021 ·The Journal of Arthroplasty ·Osman Ahmed, (unknown), Mikin Patel, Hue H. Luu, (unknown), Kenneth S. Cohen	5
3	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas 2021 ·Haematologica ·Ajay Major, Justin Kline, Theodore Karrison, Paul A. S. Fishkin, Amy Kimball, Adam M. Petrich, Sreenivasa Nattam, Krishna Rao, Bethany Sleckman, Kenneth S. Cohen, Koen van Besien, Aaron P. Rapoport, Sonali M. Smith	21
4	Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study 2014 ·European Heart Journal ·Nicolas Amabile, Susan Cheng, (unknown), Martin G. Larson, Anahita Ghorbani, Elizabeth L. McCabe, Gabriel K. Griffin, Coralie L. Guérin, Jennifer E. Ho, Stanley Y. Shaw, Kenneth S. Cohen, Ramachandran S. Vasan, Alain Tedgui, Chantal M. Boulanger, Thomas J. Wang	181
5	Temsirolimus (TEM) and lenalidomide (LEN) in relapsed/refractory Hodgkin lymphoma including in patients with prior exposure to brentuximab vedotin (BV). 2014 ·Journal of Clinical Oncology ·Jagoda Jasielec, Amy Kimball, Kenneth S. Cohen, Justin Kline, Aaron P. Rapoport, Adam M. Petrich, Chadi Nabhan, Sachdev Thomas, L. Austin Doyle, Walter M. Stadler, Theodore Karrison, Sonali M. Smith	2
6	Circulating CD31+ leukocyte frequency is associated with cardiovascular risk factors 2013 ·Atherosclerosis ·Yin Ge, Susan Cheng, Martin G. Larson, Anahita Ghorbani, Roderick P. Martin, Rachael Klein, Christopher J. O’Donnell, Ramachandran S. Vasan, Stanley Y. Shaw, Thomas J. Wang, Kenneth S. Cohen	9
7	Circulating angiogenic cell populations, vascular function, and arterial stiffness 2011 ·Atherosclerosis ·Susan Cheng, Na Wang, Martin G. Larson, Joseph Palmisano, Gary F. Mitchell, Emelia J. Benjamin, Ramachandran S. Vasan, Daniel Levy, Elizabeth L. McCabe, Joseph A. Vita, Thomas J. Wang, Stanley Y. Shaw, Kenneth S. Cohen, Naomi M. Hamburg	12
8	Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma 2011 ·PubMed ·Neil S. Horowitz, Richard T. Penson, Dan G. Duda, Emmanuelle di Tomaso, Yves Boucher, Marek Ancukiewicz, Kenneth S. Cohen, Suzanne Berlin, Carolyn Krasner, Marsha A. Moses, Rakesh K. Jain	17
9	Blockade of Tumor Necrosis Factor α Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy 2010 ·Cancer Research ·Yuru Meng, Michael A. Beckett, Hua Liang, Helena J. Mauceri, Nico van Rooijen, Kenneth S. Cohen, Ralph R. Weichselbaum	144
10	Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma 2010 ·Journal of Clinical Oncology ·Tracy T. Batchelor, Dan G. Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Scott R. Plotkin, Elizabeth R. Gerstner, April F. Eichler, Jan Drappatz, Fred H. Hochberg, Thomas Benner, David N. Louis, Kenneth S. Cohen, (unknown), (unknown), Jay S. Loeffler, Marsha A. Moses, Percy Ivy, A. Gregory Sorensen, Patrick Y. Wen, Rakesh K. Jain	406
11	Association of Colony-Forming Units With Coronary Artery and Abdominal Aortic Calcification 2010 ·Journal of Vascular Surgery ·SW Cheng, Kenneth S. Cohen, Stanley Y. Shaw	1
12	The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma 2010 ·Blood Cells Molecules and Diseases ·Sonali M. Smith, John Anastasi, Kenneth S. Cohen, Lucy A. Godley	48
13	T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse 2010 ·Leukemia & lymphoma ·Vaishalee P. Kenkre, (unknown), Andrew Artz, Chuanhong Liao, Kenneth S. Cohen, Lucy A. Godley, Justin Kline, Sonali M. Smith, Wendy Stock, Koen van Besien	9
14	VEGFR2⁺PDGFRβ⁺ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI) 2009 ·Journal of Cellular and Molecular Medicine ·Rosemary Jones, Diane E. Capen, Margaretha Jacobson, Kenneth S. Cohen, David T. Scadden, Dan G. Duda	10
15	A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents 2008 ·Nature Protocols ·Rosemary Jones, Diane E. Capen, Kenneth S. Cohen, Lance L. Munn, Rakesh K. Jain, Dan G. Duda	8
16	At the Canyon’s Edge: Depression in American Indian Culture 2008 ·EXPLORE ·Kenneth S. Cohen	3
17	Therapeutic targeting of a stem cell niche 2007 ·Nature Biotechnology ·Gregor B. Adams, Roderick P. Martin, (unknown), Karissa T. Chabner, Kenneth S. Cohen, Laura M. Calvi, Henry M. Kronenberg, David T. Scadden	219
18	Silencing p21Waf1/Cip1/Sdi1 expression increases gene transduction efficiency in primitive human hematopoietic cells 2005 ·Gene Therapy ·(unknown), Eyal C. Attar, Kenneth S. Cohen, Clyde S. Crumpacker, David T. Scadden	30
19	Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo breakdown → 2005 ·Nature Medicine ·Mark Stroh, John P. Zimmer, Dan G. Duda, Tatyana Levchenko, Kenneth S. Cohen, Edward B. Brown, David T. Scadden, Vladimir P. Torchilin, Moungi G. Bawendi, Dai Fukumura, Rakesh K. Jain	322
20	Non-Hodgkin’s Lymphoma: Pathogenesis, Clinical Presentation, and Treatment 2001 ·Cancer treatment and research ·Kenneth S. Cohen, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact